Editas, Millennium vet launches new biotech with $56M from Third Rock

As one of the first scientists at cancer drug developer Millennium Pharmaceuticals in the early 1990s, and later the first employee of gene editing firm Editas Medicine in 2013, Sandra Glucksmann knows a thing or two about successful startups. With her latest project, she ’s hoping to strike biotech gold yet again. Cambridge-based Cedilla Therapeutics officially launched on Tuesday with $56 million in financing from Third Rock Ventures. Glucksmann, who left her post as Editas’ chief operating…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news